hu1124. Antipsoriatic, treatment of transplant rejection

Drugs of the Future

Volumn 26, Issue 3, 2001, Pages 232-238

  Sorbera, L A ^a   Leeson, P A ^a   Graul, A ^a   Revel, L ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

1 chain); Anti (human CD11a antigen ) (human mouse monoclonal hu1124; Dimer; Disulfide with human mouse monoclonal hu1124 light chain; Immunoglobulin G1

Indexed keywords

ALEFACEPT; ANTIPSORIASIS AGENT; CEDELIZUMAB; DENILEUKIN DIFTITOX; EFALIZUMAB; GALIXIMAB; HU 1124; HUMAX; IC 747; INTERLEUKIN 2 RECEPTOR ANTIBODY; IR 502; MONOCLONAL ANTIBODY CD11A; MONOCLONAL ANTIBODY IDEC 131; MONOCLONAL ANTIBODY M 291; MONOCLONAL ANTIBODY MHM24; OKT 4; SIPLIZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GRAFT REJECTION; HEADACHE; HUMAN; MULTICENTER STUDY; PSORIASIS;

EID: 0034994004     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.03.611646     Document Type: Article

References (29)

1. The cytokine network in psoriasis
2. Treatment of psoriasis
3. Cell kinetics in psoriasis: The use of animal and human skin models
4. Dermal injection of immunocytes induces psoriasis
5. Response of psoriasis to a new topical retinoid, AGN 190168
6. Changes in keratinocyte maturation during wound healing
7. Cellular actions of etretinate in psoriasis: Enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes
8. Psoriasis in monozygotic twins: Variations in expression in individuals with identical genetic constitution
9. The immunopathology of psoriasis
10. Epidermal T lymphocytes and HLA-DR expression in psoriasis
11. Evidence for the involvement of bacterial superantigens in psoriasis, atopic dermatitis, and Kawasaki syndrome
12. Cross-reactivity between streptococcal M surface antigen and human skin
13. Psoriasis: A possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis
14. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1
15. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis
16. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis
17. Pharmacokinetics and pharmacodynamics of subcutaneously administered anti-CD11a (hu1124) in psoriasis subjects
18. Pharmacokinetics and pharmacodynamics of subcutaneously administered anti-CD11a (hu1124) in psoriasis subjects
19. Anti-CD11a: 12 Week trial of subcutaneous administration in patients with moderate to severe plaque psoriasis
20. Anti-CD11: Results of a 12-week trial of subcutaneous administration in patients with moderate to severe plaque psoriasis
21. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking
22. Clinical and histologic effects of subcutaneously administered anti-CD11a (hu1124) in patients with psoriasis
23. Psoriasis is clinically and histologically improved by treatment with a humanized anti-CD11a monoclonal antibody (hu1124): Results of a multicenter, multiple ascending dose study
24. hu1124 improves dermatologic-specific quality of life in subjects with moderate-to-severe psoriasis
25. Treatment of moderate to severe psoriasis with a second course of anti-CD11a: Results from an open label study